Figure S1. H&E staining and IHC staining of Sox2 in xenograft tumors from mice that had been injected with Hep3B cells (magnification, x40). H&E, hematoxylin and eosin; miRNA, microRNA; IHC, immunohistochemical.



Figure S2. MiR-HCC2 directly targets the 3'-UTR of BAMBI and upregulates its expression. (A) Putative and mutant binding sites for miR-HCC2 on the 3'-UTR of BAMBI. EGFP reporter analyses in Huh7 cells were performed by co-transfection of pcDNA3/EGFP vectors containing (B) BAMBI wild-type or (C) mutated putative binding sites in the 3'-UTR and the miR-HCC2 expression vector or ASO-miR-HCC2. (D) Relative mRNA and protein expression levels of BAMBI at 48 h after transfection with miR-HCC2 or ASO-miR-HCC2 in HepG2 and Huh7 cells. The samples derived from the same experiment and the blots were processed in parallel. (E) Relative mRNA expression levels of BAMBI in liver cancer tissues and adjacent non-tumor tissues were evaluated using reverser transcription-quantitative PCR (n=13). (F) Correlation analysis of miR-HCC2 and BAMBI expression levels in liver cancer tissues. All results were compared with corresponding control groups. Data are presented as mean ± standard deviation. *P<0.05; **P<0.01 and ***P<0.001 compared with the corresponding control group (miR-HCC2 vs. pcDNA3 and ASO-miR-HCC2 vs. ASO-NC). BAMBI, bone morphogenic protein and activin membrane-bound inhibitor homolog; miR, micro RNA; mut, mutant; EGFP, enhanced GFP; ASO, antisense oligonucleotide; NC, negative control; ns, not significant.



Figure S3. The efficiency of YY1 and shR-YY1 vectors in Huh7 cells were examined. The samples derived from the same experiment and the blots were processed in parallel. *P<0.05 and **P<0.01 compared with the corresponding control (YY1 vs. pcDNA3 and shR-YY1 vs. pSilencer-NC). shR, short hairpin RNA; NC, negative control.